The Efficacy and Safety of Fecal Microbiota Transplantation Combined With Biofeedback for Mixed Constipation: A Retrospective Cohort Study

Bo Yang, Hongliang Tian, Chen Ye, Lin Zhiliang, Di Zhao, Chunlian Ma, Jiangman Zhao, Shouxin Wu, Rongfeng Jiang, Ning Li, Huanlong Qin, Qiyi ChenFrontiers in Medicine 2021 · DOI

Abstract

This study aims to assess the effectiveness and safety of fecal microbiota transplantation (FMT) combined with biofeedback for patients with mixed constipation. Patients who received biofeedback (biofeedback group, n = 40) and those who received FMT combined with biofeedback (FMT combination group, n = 45) were enrolled. Spontaneous bowel movements (SBMs) frequency, Bristol Stool Form Scale (BSFS), and Patient Assessment of Constipation Symptoms (PAC-SYM) score were analyzed to evaluate the effect of treatment. Gastrointestinal Quality of Life Index (GIQLI) scores of patients were used to assess the quality of life, and the safety of FMT combination therapy was evaluated by the presence of adverse events. The 16S rRNA gene sequencing was performed on the fecal samples of 12 donors, feces of 31 patients before and after receiving FMT combination treatment. Comparing the biofeedback group and the FMT combination group 1 month after the treatment, significant differences were observed in the mean value of SBM frequency, BSFS, and PAC-SYM scores, which were 2.15 ± 1.05 vs. 3.61 ± 0.89 (p = 0.0031), 2.1 ± 0.9 vs. 2.5 ± 1.2 (p = 0.008), and 2.4 ± 0.5 vs. 2.2 ± 0.6 (p = 0.0021), respectively. Meanwhile, FMT combination therapy had long-term beneficial effects according to the data collected at six months and 12 months after the treatment. With respect to the quality of life, GIQLI scores were higher in the FMT combination group (103.6 ± 15.1) compared with that in the biofeedback group (88.7 ± 10.1) one month after administration (p = 0.0042). In addition, there were no significant differences between the two groups in adverse events, including abdominal pain, diarrhea, dizziness, nausea, vomiting, and other side effects. Results of 16S rRNA gene sequencing showing some well-known probiotics had significantly increased after FMT combination treatment compared with pre-FMT samples, such as Prevotella and Bifidobacterium. Findings of this study suggested that FMT combined with biofeedback could be effective and safe for patients with mixed constipation.

Introduction

Chronic constipation is a significant global health burden, affecting up to 20% of the population. It is often categorized into slow-transit constipation (STC) and outlet obstructive constipation. "Mixed constipation" represents a particularly challenging subset where patients suffer from both slow colonic transit and mechanical dysfunction during defecation. While biofeedback therapy is a standard treatment for mechanical issues, its efficacy is often limited in mixed cases where underlying microbial dysbiosis persists. This study investigates whether "resetting" the gut microbiome via Fecal Microbiota Transplantation (FMT) can act as a synergistic catalyst to improve clinical outcomes in these complex patients.

Methods

Researchers conducted a retrospective cohort study comparing two treatment strategies:

  1. Biofeedback Group (n=40): Received 20 sessions of biofeedback training over one month.
  2. FMT Combination Group (n=45): Received a three-day vancomycin course and bowel lavage, followed by six consecutive days of FMT (delivered via nasoduodenal tube), alongside the standard biofeedback regimen.

Clinical success was measured using Spontaneous Bowel Movements (SBMs) per week, the Bristol Stool Form Scale (BSFS), and the Gastrointestinal Quality of Life Index (GIQLI). To evaluate the biological mechanism, 16S rRNA gene sequencing was performed on fecal samples from 12 donors and 31 patients (pre- and post-treatment).

Clinical Outcomes

The FMT combination group significantly outperformed the biofeedback-only group across all primary clinical metrics. At the one-month mark, the combination group averaged 3.61 SBMs/week compared to 2.15 in the biofeedback group (p = 0.0031). Notably, this clinical advantage was not merely temporary; the improvements were largely sustained at the 6-month and 12-month follow-up intervals.

SBM frequency (times per week) over 12 months shows sustained improvement in the FMT combination group compared to the biofeedback-only group.

Microbiome Remodeling

Analysis of the 16S rRNA sequencing data revealed that FMT induced a fundamental shift in the patients' gut profiles. Alpha diversity indices, which measure the richness and evenness of the microbial community, showed significant increases following treatment, moving closer to the diversity levels seen in healthy donors.

Alpha diversity indices (ACE, Chao, Shannon, Simpson) demonstrate a significant increase in microbial richness and diversity in patients following FMT combination treatment.

Post-FMT patients showed a significant increase in beneficial genera such as Bifidobacterium and Prevotella, while the abundance of Bacteroides (often elevated in constipation patients) decreased. This suggests that the "new" microbiome successfully colonized and created a more favorable environment for colonic motility.

Safety and Quality of Life

Quality of life, as measured by the GIQLI, was significantly higher in the combination group (103.6) compared to the biofeedback group (88.7) at one month (p = 0.0042). Regarding safety, there were no significant differences in adverse events between the two groups. Reported side effects, such as abdominal pain or nausea, were mild and self-limiting, confirming that the intensive FMT regimen was well-tolerated.

Discussion and Conclusion

This study provides strong evidence that a "double-hit" approach—addressing both the mechanical (biofeedback) and microbial (FMT) drivers of mixed constipation—is superior to biofeedback alone. While the retrospective nature and limited sequencing sample size are noted limitations, the findings suggest that FMT offers a safe and effective way to "re-tune" the gut for long-term relief in patients with complex constipation profiles.

Summary updated

Abstract

This study aims to assess the effectiveness and safety of fecal microbiota transplantation (FMT) combined with biofeedback for patients with mixed constipation. Patients who received biofeedback (biofeedback group, <i>n</i> = 40) and those who received FMT combined with biofeedback (FMT combination group, <i>n</i> = 45) were enrolled. Spontaneous bowel movements (SBMs) frequency, Bristol Stool Form Scale (BSFS), and Patient Assessment of Constipation Symptoms (PAC-SYM) score were analyzed to evaluate the effect of treatment. Gastrointestinal Quality of Life Index (GIQLI) scores of patients were used to assess the quality of life, and the safety of FMT combination therapy was evaluated by the presence of adverse events. The 16S rRNA gene sequencing was performed on the fecal samples of 12 donors, feces of 31 patients before and after receiving FMT combination treatment. Comparing the biofeedback group and the FMT combination group 1 month after the treatment, significant differences were observed in the mean value of SBM frequency, BSFS, and PAC-SYM scores, which were 2.15 ± 1.05 vs. 3.61 ± 0.89 (<i>p</i> = 0.0031), 2.1 ± 0.9 vs. 2.5 ± 1.2 (<i>p</i> = 0.008), and 2.4 ± 0.5 vs. 2.2 ± 0.6 (<i>p</i> = 0.0021), respectively. Meanwhile, FMT combination therapy had long-term beneficial effects according to the data collected at six months and 12 months after the treatment. With respect to the quality of life, GIQLI scores were higher in the FMT combination group (103.6 ± 15.1) compared with that in the biofeedback group (88.7 ± 10.1) one month after administration (<i>p</i> = 0.0042). In addition, there were no significant differences between the two groups in adverse events, including abdominal pain, diarrhea, dizziness, nausea, vomiting, and other side effects. Results of 16S rRNA gene sequencing showing some well-known probiotics had significantly increased after FMT combination treatment compared with pre-FMT samples, such as Prevotella and Bifidobacterium. Findings of this study suggested that FMT combined with biofeedback could be effective and safe for patients with mixed constipation.
BibTeX
@inproceedings{yang2021efficacy,
  author = {Bo Yang and Hongliang Tian and Chen Ye and Lin Zhiliang and Di Zhao and Chunlian Ma and Jiangman Zhao and Shouxin Wu and Rongfeng Jiang and Ning Li and Huanlong Qin and Qiyi Chen},
  title = {{The Efficacy and Safety of Fecal Microbiota Transplantation Combined With Biofeedback for Mixed Constipation: A Retrospective Cohort Study}},
  booktitle = {Frontiers in Medicine},
  year = {2021},
  doi = {10.3389/fmed.2021.746990},
}
Figure